[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100513804":3},{"organization":4,"outcomesModule":7,"designInfo":15,"detailedDescription":11,"studyPopulation":18,"armGroups":11,"interventions":11,"overallOfficials":11,"centralContacts":19,"locations":25,"responsibleParty":42,"collaborators":11,"id":44,"slug":11,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":11,"eligibilityCriteria":49,"healthyVolunteers":45,"sex":50,"minAge":51,"maxAge":11,"enrollmentInfo":52,"targetDuration":11,"studyType":55,"phases":11,"briefSummary":56,"conditions":57,"keywords":11,"overallStatus":28,"whyStopped":11,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"Boryung Pharmaceutical Co., Ltd","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9,13],{"measure":10,"description":11,"timeFrame":12},"Target blood pressure control rate",null,"12weeks after administration",{"measure":14,"description":11,"timeFrame":12},"Target blood glucose achievement rate",{"allocation":11,"interventionModel":11,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":16,"timePerspective":17,"maskingInfo":11},"COHORT","PROSPECTIVE","Patients with type 2 diabetes mellitus accompanied by hypertension who are scheduled to be administrated Trudapa Tab. or Trudapa M SR Tab.",[20],{"name":21,"role":22,"phone":23,"phoneExt":11,"email":24},"Shinyoung Oh","CONTACT","+82-2-708-8000","syoh@boryung.co.kr",[26],{"facility":27,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":11,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Gachon University Gil Medical Center","RECRUITING","Incheon","Namdong-gu","21565","South Korea",{"type":34,"coordinates":35},"Point",[36,37],126.70515,37.45646,{"lat":37,"lon":36},[40],{"name":41,"role":22,"phone":11,"phoneExt":11,"email":11},"Ki-young Lee",{"type":43,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100513804",false,"NCT05970237","A Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patient With Type 2 Diabetes Mellitus and Hypertension","A Multicenter, Prospective, Non-interventional, Observational Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patient With Type 2 Diabetes Mellitus and Hypertension","Inclusion Criteria:\n\n* Those diagnosed with type 2 diabetes mellitus accompanied by hypertension who are scheduled to be administrated Trudapa Tab. or Trudapa M SR Tab.\n* Those who voluntarily signed a written personal information agreement to participate in this clinical study.\n* Those able to understand this study, be cooperative in the execution of the study, and participate in the study until its completion.\n\nExclusion Criteria:\n\n* Patients with secondary hypertension: Secondary hypertension is not limited to the following diseases; (e.g., coarctation of the aorta, hyperaldosteronism, renal artery stenosis, pheochromocytoma, Cushing's syndrome and polycystic kidney disease, etc.)\n* Those who have a history of taking dapagliflozin within 4 weeks of baseline (Visit 1)\n* Those who are expected to need insulin prescription during the study period\n* Pregnant women, breast-feeding women","ALL","19 Years",{"count":53,"type":54},9000,"ESTIMATED","OBSERVATIONAL","The purpose of this clinical trial is to evaluate the efficacy and safety of dapagliflozin in patient with type 2 diabetes mellitus and hypertension",[58,59],"Diabetes Mellitus","Hypertension","2025-09-11",{"date":62,"type":63},"2025-09-15","ACTUAL",{"date":65,"type":63},"2023-07-26",{"date":67,"type":54},"2025-10-21",{"name":5,"class":6},1]